PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24586940-7	2014	Pressure-induced platelet aggregation, PAC-1 binding, and translocation and release of CD40L were all attenuated by the PPARgamma agonist Thiazolidinediones (TZDs).	Thiazolidinediones	138-156	CD40 ligand	Homo sapiens	87-92	
19490202-4	2009	DISCUSSION: Thiazolidinediones attenuate circulating levels of pro-inflammatory mediators in patients with type 2 diabetes, including C-reactive protein, interleukin-6, CD40L, monocyte chemoattractant protein-1 and metalloproteinase-9.	Thiazolidinediones	12-30	CD40 ligand	Homo sapiens	169-174	
15280513-9	2004	Statins, glitazones, glycoprotein IIb/IIIa inhibitors, and clopidogrel have been demonstrated to effectively reduce CD40L levels both in vitro and in vivo.	Thiazolidinediones	9-19	CD40 ligand	Homo sapiens	116-121	
12742991-2	2003	This study therefore evaluated the hypothesis that diabetic patients have elevated plasma levels of soluble CD40L (sCD40L) and that treatment with the insulin-sensitizing thiazolidinediones lowers this index of inflammation.	Thiazolidinediones	171-189	CD40 ligand	Homo sapiens	108-113	
24586940-7	2014	Pressure-induced platelet aggregation, PAC-1 binding, and translocation and release of CD40L were all attenuated by the PPARgamma agonist Thiazolidinediones (TZDs).	Thiazolidinediones	158-162	CD40 ligand	Homo sapiens	87-92